Prostate-Specific Antigen Density Predicts Adverse Pathology and Increased Risk of Biochemical Failure

Urology

Volumn 69, Issue 6, 2007, Pages 1121-1127

  Radwan, Mohamed H ^a   Yan, Yan ^a   Luly, Jason R ^a   Figenshau, Robert S ^a   Brandes, Steven B ^a   Bhayani, Sam B ^a   Bullock, Arnold D ^a   Liefu, Ye ^a   Andriole, Gerald L ^a   Kibel, Adam S ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANTIGEN DETECTION; ARTICLE; BIOCHEMICAL FAILURE; CHEMICAL PARAMETERS; HUMAN; MAJOR CLINICAL STUDY; MALE; NOMOGRAM; ORGAN WEIGHT; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATE SPECIFIC ANTIGEN DENSITY; PROSTATECTOMY; RISK ASSESSMENT; STATISTICAL ANALYSIS; ULTRASOUND;

AGED; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; ORGAN SIZE; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK ASSESSMENT; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 34249990391     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2007.01.087     Document Type: Article

References (21)

1. Partin A.W., Mangold L.A., Lamm D.M., et al. Contemporary update of prostate cancer staging nomograms (Partin tables) for the new millennium. Urology 58 (2001) 843-848
2. Kattan M.W., Wheeler T.M., and Scardino P.T. Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. J Clin Oncol 17 (1999) 1499-1507
3. Kattan M.W., Eastham J.A., Stapleton A.M., et al. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 90 (1998) 766-771
4. Benson M.C., Whang I.S., Pantuck A., et al. Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer. J Urol 147 (1992) 815-816
5. Freedland S.J., Wieder J.A., Jack G.S., et al. Improved risk stratification for biochemical recurrence after radical prostatectomy using a novel risk group system based on prostate specific antigen density and biopsy Gleason score. J Urol 168 (2002) 110-115
6. Seaman E.K., Whang I.S., Cooner W., et al. Predictive value of prostate-specific antigen density for the presence of micrometastatic carcinoma of the prostate. Urology 43 (1994) 645-648
7. Horninger W., Rogatsch H., Reissigl A., et al. Correlation between preoperative predictors and pathologic features in radical prostatectomy specimens in PSA-based screening. Prostate 40 (1999) 56-61
8. Pollack A., Lankford S., Zagars G.K., et al. Prostate specific antigen density as a prognostic factor for patients with prostate carcinoma treated with radiotherapy. Cancer 77 (1996) 1515-1523
9. Ingenito A.C., Ennis R.D., Hsu I.C., et al. Re-examining the role of prostate-specific antigen density in predicting outcome for clinically localized prostate cancer. Urology 50 (1997) 73-78
10. Freedland S.J., Kane C.J., Presti Jr. J.C., et al. Comparison of preoperative prostate specific antigen density and prostate specific antigen for predicting recurrence after radical prostatectomy: results from the SEARCH database. J Urol 169 (2003) 969-973
11. Corn B.W., Hanks G.E., Lee W.R., et al. Prostate specific antigen density is not an independent predictor of response for prostate cancer treated by conformal radiotherapy. J Urol 153 (1995) 1855-1859
12. Brassell S.A., Kao T.C., Sun L., et al. Prostate-specific antigen versus prostate-specific antigen density as predictor of tumor volume, margin status, pathologic stage, and biochemical recurrence of prostate cancer. Urology 66 (2005) 1229-1233
13. Stamey T.A., Caldwell M., McNeal J.E., et al. The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years?. J Urol 172 (2004) 1297-1301
14. Carvalhal G.F., Humphrey P.A., Thorson P., et al. Visual estimate of the percentage of carcinoma is an independent predictor of prostate carcinoma recurrence after radical prostatectomy. Cancer 89 (2000) 1308-1314
15. Harrell Jr. F.E., Lee K.L., and Mark D.B. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 15 (1996) 361-387
16. Hanley J.A., and McNeil B.J. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 143 (1982) 29-36
17. Tarone R.E., Chu K.C., and Brawley O.W. Implications of stage-specific survival rates in assessing recent declines in prostate cancer mortality rates. Epidemiology 11 (2000) 167-170
18. Albertsen P.C., Hanley J.A., and Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 293 (2005) 2095-2101
19. Kibel A.S. An interdisciplinary approach to treating prostate cancer. Urology 65 (2005) 13-18
20. Aref I., Eapen L., Agboola O., et al. Is prostate specific antigen density an important prognostic indicator for patients with prostate cancer treated with external beam therapy?. Br J Radiol 71 (1998) 868-871
21. Hendrikx A.J., van Helvoort-van Dommelen C.A., van Dijk M.A., et al. Ultrasonic determination of prostatic volume: a cadaver study. Urology 34 (1989) 123-125